Stock-Based Compensation
The latest quarterly stock-based comp is $20.00 Million. Stock-Based Compensation (SBC) is the expense recognized for equity awards (stock options, RSUs) granted to employees. It's a non-cash expense that dilutes existing shareholders.
DGX Stock-Based Comp
Reported quarterly stock-based compensation; no daily interpolation.
Current Stock-Based Comp
$20.00M
$20.00 Million
Quarter-over-Quarter Change
N/A
vs. $0 prior quarter
Historical Data
96
Quarters of data available
Quarterly Stock-Based Comp History
| Period | Stock-Based Comp | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $20.00M | +$20.00M | — |
| Q4 2025 | $0 | $-20.00M | -100.00% |
| Q3 2025 | $20.00M | $-1.00M | -4.76% |
| Q2 2025 | $21.00M | $-1.00M | -4.55% |
| Q1 2025 | $22.00M | $-5.00M | -18.52% |
| Q4 2024 | $27.00M | +$8.00M | +42.11% |
| Q3 2024 | $19.00M | $-1.00M | -5.00% |
| Q2 2024 | $20.00M | $-2.00M | -9.09% |
| Q1 2024 | $22.00M | +$3.00M | +15.79% |
| Q4 2023 | $19.00M | +$1.00M | +5.56% |
| Q3 2023 | $18.00M | +$2.00M | +12.50% |
| Q2 2023 | $16.00M | $-8.00M | -33.33% |
| Q1 2023 | $24.00M | +$2.00M | +9.09% |
| Q4 2022 | $22.00M | +$4.00M | +22.22% |
| Q3 2022 | $18.00M | $-1.00M | -5.26% |
| Q2 2022 | $19.00M | +$1.00M | +5.56% |
| Q1 2022 | $18.00M | $-1.00M | -5.26% |
| Q4 2021 | $19.00M | $-2.00M | -9.52% |
| Q3 2021 | $21.00M | +$0 | 0.00% |
| Q2 2021 | $21.00M | +$3.00M | +16.67% |
| Q1 2021 | $18.00M | $-16.00M | -47.06% |
| Q4 2020 | $34.00M | +$2.00M | +6.25% |
| Q3 2020 | $32.00M | +$15.00M | +88.24% |
| Q2 2020 | $17.00M | +$3.00M | +21.43% |
| Q1 2020 | $14.00M | +$2.00M | +16.67% |
| Q4 2019 | $12.00M | +$0 | 0.00% |
| Q3 2019 | $12.00M | $-3.00M | -20.00% |
| Q2 2019 | $15.00M | $-2.00M | -11.76% |
| Q1 2019 | $17.00M | +$9.00M | +112.50% |
| Q4 2018 | $8.00M | $-11.00M | -57.89% |
| Q3 2018 | $19.00M | +$4.00M | +26.67% |
| Q2 2018 | $15.00M | $-4.00M | -21.05% |
| Q1 2018 | $19.00M | $-6.00M | -24.00% |
| Q4 2017 | $25.00M | +$8.00M | +47.06% |
| Q3 2017 | $17.00M | $-3.00M | -15.00% |
| Q2 2017 | $20.00M | +$3.00M | +17.65% |
| Q1 2017 | $17.00M | +$0 | 0.00% |
| Q4 2016 | $17.00M | +$1.00M | +6.25% |
| Q3 2016 | $16.00M | $-2.00M | -11.11% |
| Q2 2016 | $18.00M | +$0 | 0.00% |
| Q1 2016 | $18.00M | +$5.00M | +38.46% |
| Q4 2015 | $13.00M | +$1.00M | +8.33% |
| Q3 2015 | $12.00M | $-3.00M | -20.00% |
| Q2 2015 | $15.00M | +$3.00M | +25.00% |
| Q1 2015 | $12.00M | $-1.00M | -7.69% |
| Q4 2014 | $13.00M | +$0 | 0.00% |
| Q3 2014 | $13.00M | +$0 | 0.00% |
| Q2 2014 | $13.00M | +$1.00M | +8.33% |
| Q1 2014 | $12.00M | +$8.11M | +208.25% |
| Q4 2013 | $3.89M | $-3.11M | -44.39% |
| Q3 2013 | $7.00M | $-5.00M | -41.67% |
| Q2 2013 | $12.00M | +$7.00M | +140.00% |
| Q1 2013 | $5.00M | $-2.25M | -30.99% |
| Q4 2012 | $7.25M | $-1.66M | -18.68% |
| Q3 2012 | $8.91M | $-5.20M | -36.86% |
| Q2 2012 | $14.11M | $-5.96M | -29.69% |
| Q1 2012 | $20.07M | $-1.05M | -4.97% |
| Q4 2011 | $21.12M | +$5.52M | +35.39% |
| Q3 2011 | $15.60M | $-650,000 | -4.00% |
| Q2 2011 | $16.25M | $-2.70M | -14.24% |
| Q1 2011 | $18.95M | +$10.06M | +113.22% |
| Q4 2010 | $8.88M | $-7.58M | -46.04% |
| Q3 2010 | $16.47M | $-981,000 | -5.62% |
| Q2 2010 | $17.45M | +$6.32M | +56.81% |
| Q1 2010 | $11.13M | $-10.60M | -48.79% |
| Q4 2009 | $21.73M | +$1.56M | +7.76% |
| Q3 2009 | $20.16M | +$27,000 | +0.13% |
| Q2 2009 | $20.14M | +$7.11M | +54.56% |
| Q1 2009 | $13.03M | +$13.03M | — |
| Q4 2008 | $0 | +$0 | — |
| Q3 2008 | $0 | +$0 | — |
| Q2 2008 | $0 | $-21.23M | -100.00% |
| Q1 2008 | $21.23M | +$21.23M | — |
| Q4 2007 | $0 | +$0 | — |
| Q3 2007 | $0 | +$0 | — |
| Q2 2007 | $0 | $-16.08M | -100.00% |
| Q1 2007 | $16.08M | +$16.08M | — |
| Q4 2006 | $0 | +$0 | — |
| Q3 2006 | $0 | +$0 | — |
| Q2 2006 | $0 | $-19.38M | -100.00% |
| Q1 2006 | $19.38M | +$19.38M | — |
| Q4 2005 | $0 | +$0 | — |
| Q3 2005 | $0 | +$0 | — |
| Q2 2005 | $0 | +$0 | — |
| Q1 2005 | $0 | +$0 | — |
| Q4 2004 | $0 | +$0 | — |
| Q3 2004 | $0 | +$0 | — |
| Q2 2004 | $0 | +$0 | — |
| Q1 2004 | $0 | +$0 | — |
| Q4 2003 | $0 | +$0 | — |
| Q3 2003 | $0 | +$0 | — |
| Q2 2003 | $0 | +$0 | — |
| Q1 2003 | $0 | +$0 | — |
| Q4 2002 | $0 | +$0 | — |
| Q3 2002 | $0 | +$0 | — |
| Q2 2002 | $0 | — | — |
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis